试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-02-15
Safety and Pharmacokinetics of Oral F901318 (Fluconazole and Posaconazole) IN Aml Leukaemia
编号:NCT03036046登记状态:入组前撤回企业 / 申办者:F2G Ltd
药物 / 成分:F901318 with fluconazole low dose、F901318 with fluconazole high dose、F901318 with posaconazole
登记的停止原因(原文):Study no longer required
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-02-15
Preliminary Investigation of ViaShield™ Amnion Patch as an Anti-Adhesive Barrier in Hemicraniectomies
编号:NCT03371316登记状态:入组前撤回企业 / 申办者:Globus Medical Inc
药物 / 成分:ViaShield
登记的停止原因(原文):Site is no longer participating in study
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-02-14
A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer
编号:NCT00388700登记状态:入组前撤回企业 / 申办者:Galectin Therapeutics Inc.
药物 / 成分:GM-CT-01、5-Fluorouracil, Leukovorin, bevacizumab
登记的停止原因(原文):Financing and re-organization
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-02-13
Enhancement of Functional Recovery After Peripheral Nerve Injury With Tacrolimus
编号:NCT00950391登记状态:入组前撤回企业 / 申办者:Washington University School of Medicine
药物 / 成分:Tacrolimus
登记的停止原因(原文):PI unable to secure funding for the project so study was not pursued.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-02-13
Phase Ib/II Study Assessing the Neo-adjuvant Combination Therapy of Vinflunine With Cisplatin Followed by Radical Cystectomy in Patients With Muscle-invasive Bladder Cancer (JaNEO)
编号:NCT02845050登记状态:入组前撤回企业 / 申办者:Ligartis GmbH
药物 / 成分:Vinflunine、Cisplatin、Radical cystectomy
登记的停止原因(原文):No participants found
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-02-09
Combination of an Investigational Cannabinoid and Methadone for HIV-associated Neuropathy
编号:NCT00723918登记状态:入组前撤回企业 / 申办者:Washington University School of Medicine
药物 / 成分:SAB378、methadone、SAB placebo、Methadone placebo
登记的停止原因(原文):Withdrawal of pharmaceutical support from Novartis - no participants randomized
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-02-09
Cytidine- and Creatine-Containing Drug in Treating Bipolar Depression
编号:NCT01543139登记状态:入组前撤回企业 / 申办者:Ewha Womans University
药物 / 成分:Valproate+Cytidine-+Creatine-、Valproate+Cytidine-、Valproate
登记的停止原因(原文):The research project has been cancelled before any participants were enrolled.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-02-09
Neural Correlates for Therapeutic Mechanisms of Lithium in Bipolar Disorder
编号:NCT01543724登记状态:入组前撤回企业 / 申办者:Ewha Womans University
药物 / 成分:Lithium
登记的停止原因(原文):The research project has been cancelled before any participants were enrolled.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-02-09
Efficacy Mechanism of N-acetylcysteine in Patients With Posttraumatic Stress Disorder
编号:NCT01664260登记状态:入组前撤回企业 / 申办者:Ewha Womans University
药物 / 成分:N-acetylcysteine、Placebo
登记的停止原因(原文):The research project has been cancelled before any participants were enrolled.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-02-09
Combined Cytidine and Creatine-containing Drug in the Treatment of the Bipolar Depression
编号:NCT02625779登记状态:入组前撤回企业 / 申办者:Ewha Womans University Mokdong Hospital
药物 / 成分:Valproate and Placebo、Valproate and Cytidine-containing Drug、Valproate and Creatine-containing Drug
登记的停止原因(原文):The research project has been cancelled before any participants were enrolled.
查看官方原始记录 ↗